The Australian nuclear medicine company has agreed to lead a merger with ITM Isotope Technologies Munich SE, paying US$1.65 billion upfront on a cash-free, debt-free basis for a German company that supplies the raw material the entire targeted radionuclide therapy industry depends on.
Telix announces takeover of ITM to create a global radiopharmaceutical powerhouse
September 21, 2026 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast Week in Review - Series 5. Ep.35
October 9, 2026 - - Podcast -
PhRMA goes to court over price rule that uses Australia as a benchmark
October 9, 2026 - - Latest News -
GLP-1s are quickly reshaping the Australian prescription medicines market
October 9, 2026 - - Latest News -
A tale of two systems with billions shifting to the private market
October 9, 2026 - - Latest News -
Australia cannot afford complacency on life sciences, AusBiotech warns at 40
October 8, 2026 - - Latest News -
Life sciences sector warns that tax overhaul could push clinical trials offshore
October 8, 2026 - - Latest News -
Moderna and CSIRO launch five year biosecurity collaboration focused on Hendra vaccine
October 8, 2026 - - Latest News
